IP Library Granted Patent US 7,268,198
Granted Patent B2
US 7,268,198 · App. 11/087,150 · Granted Sep 11, 2007

Silicone hydrogel contact lenses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,268,198
App. No.
11/087,150
Granted
Sep 11, 2007
Kind
B2
Abstract

Silicone hydrogels, including vinyl carbonate endcapped polysiloxanes containing a fluorinated side chain, are useful as biomaterials, especially hydrogel biomaterials, including contact lens materials. The hydrogels are the hydrated polymerization product of a monomer mixture comprising a hydrophilic monomer and a polysiloxane-containing monomer, have an oxygen permeability of at least about 120 Barrers, a water content of at least about 20 weight percent, and a modulus no greater than about 83 g/mm 2 .

Claims (36)

1. A hydrogel that is the hydrated polymerization product of a monomer mixture comprising a hydrophilic monomer selected from the group consisting of N-vinyl-N-methyl acetamide, N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide, N-vinyl pyrrolidone and mixtures thereof, and a polysiloxane-containing monomer, wherein said hydrogel has an oxygen permeability of at least about 120 Barrers, a water content of at least about 20 weight percent, and a modulus from 40 to 57 g/mm 2 .

2. The hydrogel of claim 1 , having a modulus from 51 to 57 g/mm 2 .

3. The hydrogel of claim 1 , having a modulus from 40 to 51 g/mm 2 .

4. The hydrogel of claim 1 , having a water content from 23.6% to 30.5% by weight.

5. The hydrogel of claim 2 , having a water content from 23.6% to 30.5% by weight.

6. The hydrogel of claim 1 , having an oxygen permeability from 127 Barrers to 147 Barrers.

7. The hydrogel of claim 1 , wherein said monomer mixture further comprises a monofunctional polysiloxanylalkyl monomer.

8. The hydrogel of claim 7 , wherein the monofunctional polysiloxanylalkyl monomer is represented by the formula:

wherein:

X denotes —OCOO—, or —OCONR 4 — where each R 4 is H or lower alkyl;

R 3 denotes hydrogen or methyl;

h is 1 to 10; and

each R 2 independently denotes a lower alkyl or halogenated alkyl radical, a phenyl radical or a radical of the formula —Si(R 5 ) 3 wherein each R 5 is independently a lower alkyl radical or a phenyl radical.

9. The hydrogel of claim 8 , wherein the monofunctional polysiloxanylalkyl monomer is selected from the group consisting of 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbamate and 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbonate.

10. The hydrogel of claim 1 , wherein the hydrophilic monomer includes N-vinyl pyrrolidinone.

11. A contact lens made from the polymerization product of a monomer mixture that comprises a hydrophilic monomer selected from the group consisting of N-vinyl-N-methyl acetamide, N-vinyl-N-ethyl acetamide, N-vinyl-N-ethyl formamide, N-vinyl formamide, N-vinyl pyrrolidone and mixtures thereof, and a polysiloxane-containing monomer, wherein said contact lens is composed of a hydrogel having an oxygen permeability of at least about 120 Barrers, a water content of at least about 20 weight percent, and a modulus from 40 to 57 g/mm 2 .

12. The contact lens of claim 11 , having a modulus from 51 to 57 g/mm 2 .

13. The contact lens of claim 11 , having a modulus from 40 to 51 g/mm 2 .

14. The contact lens of claim 11 , having a water content from 23.6% to 30.5% by weight.

15. The hydrogel of claim 12 , having a water content from 23.6% to 30.5% by weight.

16. The contact lens of claim 11 , having an oxygen permeability from 127 Barrers to 147 Barrers.

17. The contact lens of claim 11 , wherein the hydrophilic monomer includes N-vinyl pyrrolidinone.

18. The contact lens of claim 11 , wherein said monomer mixture further comprises a monofunctional polysiloxanylalkyl monomer.

19. The contact lens of claim 18 , wherein the monofunctional polysiloxanylalkyl monomer is represented by the formula:

wherein:

X denotes —OCOO—, or —OCONR 4 — where each R 4 is H or lower alkyl;

R 3 denotes hydrogen or methyl;

h is 1 to 10; and

each R 2 independently denotes a lower alkyl or halogenated alkyl radical, a phenyl radical or a radical of the formula —Si(R 5 ) 3 wherein each R 5 is independently a lower alkyl radical or a phenyl radical.

20. The contact lens of claim 19 , wherein the monofunctional polysiloxanylalkyl monomer is selected from the group consisting of 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbamate and 3-[tris(trimethylsiloxy)silyl] propyl vinyl carbonate.

21. A hydrogel that is the hydrated polymerization product of a monomer mixture comprising a hydrophilic monomer and a polysiloxane-containing monomer, wherein said hydrogel has an oxygen permeability of at least about 120 Barrers, a water content from 23.6% to 30.5% by weight, and a modulus from 40 to 57 g/mm 2 .

22. The hydrogel of claim 21 , having a modulus from 51 to 57 g/mm 2 .

23. The hydrogel of claim 21 , having a modulus from 40 to 51 g/mm 2 .

24. A contact lens made from the polymerization product of a monomer mixture that comprises a hydrophilic monomer and a polysiloxane-containing monomer, wherein said contact lens is composed of a hydrogel having an oxygen permeability of at least about 120 Barrers, a water content from 23.6% to 30.5% by weight, and a modulus from 40 to 57 g/mm 2 .

25. The contact lens of claim 24 , having a modulus from 51 to 57 g/mm 2 .

26. The contact lens of claim 24 , having a modulus from 40 to 51 g/mm 2 .

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →